Interleukin‐17 is a potential player and treatment target in severe chronic spontaneous urticaria
Clinical & Experimental Allergy2020Vol. 50(7), pp. 799–804
Citations Over TimeTop 10% of 2020 papers
D. A. Sabag, L. Matanes, Jacob Bejar, H. Sheffer, A Barzilai, Martin K. Church, Elias Toubi, Marcus Maurer, Zahava Vadasz
Abstract
These findings suggest that IL-17 is involved in the pathogenesis of CSU and that IL-17 should be investigated as a therapeutic target in future studies with larger numbers of patients.
Related Papers
- → Bimekizumab versus Secukinumab in Plaque Psoriasis(2021)377 cited
- → Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F(2020)182 cited
- → Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential(2013)109 cited
- → (2015)
- → Omalizumab is efficacious for management of recalcitrant,antihistamine-resistant chronic urticaria(2015)